Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.6% – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares traded up 8.6% on Friday . The company traded as high as $7.00 and last traded at $6.93. 8,084,092 shares were traded during mid-day trading, an increase of 35% from the average session volume of 6,003,390 shares. The stock had previously closed at $6.38.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Up 10.8 %

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.03 billion, a PE ratio of -4.47 and a beta of 0.81. The firm has a 50-day moving average of $6.58 and a two-hundred day moving average of $7.45.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.43) earnings per share. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 165,682 shares of company stock valued at $1,088,111. Insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Recursion Pharmaceuticals during the third quarter valued at about $25,000. Farther Finance Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares during the period. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. KBC Group NV raised its holdings in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the period. Finally, Amalgamated Bank increased its position in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.